Filing Flows › BioNexus Gene Lab (BGLC) › Q1 2025
BioNexus Gene Lab (BGLC) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 15, 2025
BioNexus Gene Lab (BGLC) reported revenue of $2.1M for the first quarter 2025 (Q1 2025), -10% from a year earlier and -15% from the quarter before. Operating margin was -28.9%, net loss $623K (29.2% of revenue).
BioNexus Gene Lab, Q1 2025: revenue $2.1M (-10% year over year), operating margin -28.9%, net loss $623K, operating cash flow −$824K. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.1M | -15% | -10% |
| Operating profit | −$618K | — | — |
| Net earnings | −$623K | -279% | — |
| Operating cash flow | −$824K | — | — |
What changed
Revenue was $2.1M in Q1 2025, down 10% year over year and down 15% from the previous quarter.
Gross margin was 16.1%, up 0.7 points from a year earlier. Operating costs exceeded revenue by $618K, an operating margin of -28.9%. Operating expenses grew 117% against a revenue fall of 10%. The quarter ended with a net loss of $623K, after a profit of $348K the previous quarter.
Operating cash flow was −$824K. Non-cash charges added back $27K of depreciation. Working capital and other items used $227K. Capital expenditures of $9K exceeded it, leaving free cash flow of −$833K.
Questions
What was BioNexus Gene Lab's revenue in the first quarter 2025?
BioNexus Gene Lab (BGLC) reported revenue of $2.1M for the first quarter 2025 (Q1 2025), -10% from a year earlier and -15% from the quarter before.
Was BioNexus Gene Lab profitable in the first quarter 2025?
Operating loss was $618K (-28.9% of revenue) and net loss $623K.
Source: BioNexus Gene Lab 10-Q on SEC EDGAR.